Institution
Universidad del Valle de Guatemala
Education•Guatemala City, Guatemala•
About: Universidad del Valle de Guatemala is a education organization based out in Guatemala City, Guatemala. It is known for research contribution in the topics: Population & Public health. The organization has 437 authors who have published 584 publications receiving 13822 citations. The organization is also known as: University of the Valley of Guatemala.
Topics: Population, Public health, Latin Americans, Health care, Stove
Papers published on a yearly basis
Papers
More filters
University of Edinburgh1, University of Glasgow2, Johns Hopkins University3, University of Colorado Boulder4, University of the Witwatersrand5, International Military Sports Council6, Aga Khan University7, Medical Research Council8, King George's Medical University9, Kenya Medical Research Institute10, International Centre for Diarrhoeal Disease Research, Bangladesh11, Centers for Disease Control and Prevention12, University of Bergen13, Tribhuvan University14, University of Barcelona15, Utrecht University16, Emory University17, All India Institute of Medical Sciences18, University of Liverpool19, Boston Children's Hospital20, National Institute of Virology21, University of Zambia22, University of Health Sciences Antigua23, National Health Laboratory Service24, Chinese Center for Disease Control and Prevention25, Austral University26, University of Michigan27, Vanderbilt University28, University of New South Wales29, University of Otago30, University of Auckland31, Universidad del Valle de Guatemala32, University of Jordan33, University of Maryland, Baltimore34, National Scientific and Technical Research Council35, Research Institute for Tropical Medicine36, Pwani University College37, University of Cape Town38, University of Warwick39, Academy of Medical Sciences, United Kingdom40, Tohoku University41, École normale supérieure de Lyon42, John E. Fogarty International Center43, Charité44, Universidad Nacional de Asunción45, Tehran University of Medical Sciences46, Robert Koch Institute47, University of London48, University of New Mexico49, Capital Medical University50, Alaska Native Tribal Health Consortium51, Innlandet Hospital Trust52, Columbia University53, Mahidol University54, University of Pretoria55, Thailand Ministry of Public Health56, Peking Union Medical College57, Nagasaki University58, Public Health Foundation of India59
TL;DR: In this paper, the authors estimated the incidence and hospital admission rate of RSV-associated acute lower respiratory infection (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions.
1,470 citations
TL;DR: Despite its divergence from known influenza A virus, the bat virus is compatible for genetic exchange with human influenza viruses in human cells, suggesting the potential capability for reassortment and contributions to new pandemic or panzootic influenza A viruses.
Abstract: Influenza A virus reservoirs in animals have provided novel genetic elements leading to the emergence of global pandemics in humans. Most influenza A viruses circulate in waterfowl, but those that infect mammalian hosts are thought to pose the greatest risk for zoonotic spread to humans and the generation of pandemic or panzootic viruses. We have identified an influenza A virus from little yellow-shouldered bats captured at two locations in Guatemala. It is significantly divergent from known influenza A viruses. The HA of the bat virus was estimated to have diverged at roughly the same time as the known subtypes of HA and was designated as H17. The neuraminidase (NA) gene is highly divergent from all known influenza NAs, and the internal genes from the bat virus diverged from those of known influenza A viruses before the estimated divergence of the known influenza A internal gene lineages. Attempts to propagate this virus in cell cultures and chicken embryos were unsuccessful, suggesting distinct requirements compared with known influenza viruses. Despite its divergence from known influenza A viruses, the bat virus is compatible for genetic exchange with human influenza viruses in human cells, suggesting the potential capability for reassortment and contributions to new pandemic or panzootic influenza A viruses.
973 citations
Public Health Foundation of India1, University of Edinburgh2, University of Colorado Denver3, National Center for Immunization and Respiratory Diseases4, University of Melbourne5, Centers for Disease Control and Prevention6, Johns Hopkins University7, Medical Research Council8, Kenya Medical Research Institute9, University of Barcelona10, Health Protection Agency11, Alaska Native Tribal Health Consortium12, Research Institute for Tropical Medicine13, Boston Children's Hospital14, University of the Witwatersrand15, All India Institute of Medical Sciences16, Aga Khan University17, Universidad de Ciencias Medicas18, Universidade Federal de Goiás19, University of Buenos Aires20, United Nations Development Programme21, Universidad del Valle de Guatemala22, University of Liverpool23, Bill & Melinda Gates Foundation24, International Centre for Diarrhoeal Disease Research, Bangladesh25
TL;DR: The data suggest that although 62% of children with severe ALRI are treated in hospitals, 81% of deaths happen outside hospitals, which suggests community-based management of severe disease could be an important complementary strategy to reduce pneumonia mortality and health inequities.
597 citations
TL;DR: In a population heavily exposed to wood smoke from cooking, a reduction in exposure achieved with chimney stoves did not significantly reduce physician-diagnosed pneumonia for children younger than 18 months; the significant reduction of a third in severe pneumonia, however, if confirmed, could have important implications for reduction of child mortality.
518 citations
TL;DR: It is shown that miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leish maniasis dueto L. braziliensis in Guatemala.
Abstract: The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo-controlled study of miltefosine therapy (2.5 mg/kg per day orally for 28 days) against cutaneous leishmaniasis in Colombia and Guatemala. In regions in Colombia where Leishmania vianna panamensis is common, the per-protocol cure rates for miltefosine and placebo were 91% (40 of 44 patients) and 38% (9 of 24). These values are similar to historic values for the antimony standard of care and placebo. In regions in Guatemala where L. v. braziliensis and L. mexicana mexicana are common, the per-protocol cure rates were 53% (20 of 38) for miltefosine and 21% (4 of 19) for placebo. The miltefosine rate was lower than historic antimony cure rates of >90%. Miltefosine was well tolerated. Miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leishmaniasis due to L. v. braziliensis in Guatemala.
350 citations
Authors
Showing all 440 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Mark Brenner | 54 | 170 | 10891 |
| Gabriela Paz-Bailey | 36 | 150 | 4580 |
| John P. McCracken | 30 | 82 | 5099 |
| Byron Arana | 29 | 67 | 3474 |
| Anaite Diaz | 23 | 34 | 2471 |
| Ricardo Bressani | 22 | 81 | 1417 |
| Celia Cordon-Rosales | 22 | 49 | 1732 |
| Jacob Creswell | 21 | 81 | 1367 |
| Robert E. Klein | 19 | 34 | 1201 |
| Nidia Rizzo | 18 | 23 | 1425 |
| Carlos Rolz | 18 | 57 | 995 |
| Edwin Castellanos | 17 | 32 | 1047 |
| Robert B. MacVean | 15 | 19 | 660 |
| Carlos E. Mendoza | 14 | 21 | 1016 |
| Ana S. Gonzalez-Reiche | 14 | 44 | 1045 |